Semaglutide Market Hits Speed Bump with ₹100 Crore Excess Stock
The meteoric rise of the semaglutide therapy market in India has encountered an unexpected hurdle as sluggish sales in May trigger significant inventory concerns. After a massive surge driven by generic launches, the weight-loss drug segment is now grappling with a substantial stock overhang across the trade channel.
The Inventory Crisis: A ₹100 Crore Overhang
Following an initial period of hyper-growth, the semaglutide market is currently facing a period of stagnation. Industry estimates suggest that stockists and wholesalers are sitting on excess inventory valued at approximately ₹100 crore. This buildup has forced channel partners to adopt a cautious stance, with many halting fresh procurement from pharmaceutical manufacturers until current stocks are liquidated.
Data from the All India Organisation of Chemists and Druggists (AIOCD) highlights a significant shift in supply chain dynamics. While the standard inventory holding period typically ranges between 30 to 45 days, stockists are currently holding between 50 to 60 days of GLP-1 (semaglutide) stock. This inventory overhang poses a potential risk of losses for distributors if sales do not pick up momentum in the coming months.
From Hyper-Growth to Sudden Slowdown
The deceleration in May comes as a sharp contrast to the explosive performance witnessed in April. The obesity therapy market, valued at ₹2,000 crore, saw a massive influx of competition after semaglutide went off-patent on March 20. This patent expiry allowed major Indian pharmaceutical players—including Sun Pharma, Dr. Reddy’s, and Torrent—to flood the market with cheaper generic alternatives.
In April, the market saw a staggering 50% month-on-month (m-o-m) surge in value and an 88% jump in volume. However, according to Pharmarack data, this momentum lost steam in May. Month-on-month value growth slowed to just 6%, while unit growth moderated to 12%, signaling a cooling period for the high-demand therapy.
Regulatory Guardrails and Market Leaders
Industry executives suggest that this moderation may not be purely organic. The slowdown could be linked to recent government advisories and stricter prescribing restrictions. New guidelines announced in April stipulate that GLP-1 therapies must be prescribed exclusively by qualified specialists, which may be tempering the rapid uptake seen during the initial "gold rush."
Despite the semaglutide slowdown, certain players continue to dominate. Mounjaro (tirzepatide), marketed by Eli Lilly, remains the largest selling therapy in this segment. In May, Mounjaro's sales grew by 12%, reaching ₹136 crore. This performance contributed to the broader ₹2.5 lakh crore organized pharma retail market, which grew by nearly 11% in May, largely driven by chronic disease therapies.
Key Takeaways
- Inventory Surplus: The trade channel is currently burdened with approximately ₹100 crore in excess semaglutide stock, with wholesalers holding up to 60 days of inventory.
- Growth Moderation: After a massive 50% value surge in April following patent expiry, May saw a significant slowdown with value growth dropping to just 6%.
- Regulatory Impact: Stricter guidelines requiring specialist-only prescriptions for GLP-1 therapies are believed to be a key factor in the recent cooling of market demand.